A three-compound fat metabolism blend — SS-31, MOTS-C, and Tesamorelin — studied for mitochondrial optimization, GH axis support, and body composition. Physician-reviewed. Prescription required.
SS-31 (Elamipretide) is a mitochondria-targeted peptide that concentrates in the inner mitochondrial membrane and stabilizes cardiolipin, supporting electron-transport efficiency and cellular energy output. Tesamorelin is a GHRH analogue that drives pulsatile growth hormone release and has documented visceral fat reduction. MOTS-c is a mitochondria-derived peptide (MDP) that acts as a metabolic regulator encoded by mitochondrial DNA, primarily affecting cellular energy metabolism, insulin sensitivity, and mitochondrial function.
Together, these compounds target fat metabolism from complementary angles — SS-31 through mitochondrial energy output, MOTS-c through AMPK and insulin-sensitizing mechanisms, and Tesamorelin through GH-axis visceral fat reduction. Individual outcomes may differ. This protocol is not intended to diagnose, treat, cure, or prevent any disease.
| Mechanism | Biological Effect |
|---|---|
| Cardiolipin stabilization (SS-31) | Improved mitochondrial energy output |
| AMPK activation (MOTS-c) | Improved insulin sensitivity and glucose uptake |
| GHRH agonism (Tesamorelin) | Pulsatile GH release and visceral fat reduction |
| Reduced oxidative stress (SS-31) | Cellular recovery support |
| Mitochondrial fat oxidation | Increased energy utilization from fat |
Your physician will determine eligibility based on your complete health intake. The following profiles are commonly associated with Fat Burner Blend protocol candidates in clinical practice:
Fat Loss Protocol
Individuals with physician-confirmed adiposity seeking targeted metabolic support.
Insulin Sensitivity
Individuals with metabolic syndrome components where MOTS-c's AMPK activation may be clinically relevant.
Endurance & Energy
Athletes or executives seeking mitochondrial optimization and metabolic efficiency support.
Combination Protocol
Patients seeking mitochondrial, metabolic and GH-axis support in a single physician-reviewed injection.
Determine your candidacy
A physician will review your intake and make eligibility determination within 24–48 hours.
All outcome language below reflects what has been observed in clinical and preclinical settings. Individual outcomes may differ significantly. These are not guarantees.
Dosing is determined individually by your assigned physician. The following represents typical ranges discussed in clinical literature. Do not self-administer or adjust dosing without physician guidance.
Typical Range
20 units SubQ daily, 5 days on / 2 days off
Administration
Subcutaneous injection
Duration
12–24 weeks (physician-determined)
Frequency
Daily, 5 days on / 2 days off (physician-determined)
These ranges are indicative only. Your physician will prescribe the specific dose and schedule appropriate for your clinical profile.
Physician consultation — Virtual intake review and protocol consultation with your assigned NP/MD
Valid prescription — Issued by your attending physician upon protocol approval
Pharmacy-dispensed compound — Dispensed by our licensed 503A compounding pharmacy partner
Follow-up check-in — Physician review at protocol midpoint; reorder pathway established
Your physician will review your complete health history before determining eligibility. The following are commonly reviewed clinical considerations.